Provider review
Edessa review: four statistics under a heading reading "clinical data", and no source for any of them
Edessa puts five numbers on its homepage under a heading that reads "clinical data". An 18% average weight loss. Nine in ten patients calling it the most effective treatment they've tried. A 6.5-inch waist reduction. And 93% who kept the weight off. Not one of them names a trial, a journal, a date or a follow-up period. The last of the five is the one to stop at, because keeping the weight off is the best-documented weakness of this entire class of drug — and Edessa's number points the other way.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit EdessaOf Edessa’s 3 dated product claims documented below, 0 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $179 for 30 days (Compounded semaglutide injection, billed monthly). A matching claim does not mean the compounded product was tested or FDA-approved.
Puts five statistics under a heading reading "clinical data" and sources none of them, including one that runs against the trial record it gestures at.
Worth trusting if
- You want the dispensing pharmacies named, which two of them are, one with an address and phone number
- You want the warning that compounded drugs are not FDA-approved placed above the price rather than under it
Be skeptical if
- You are reading "93% kept the weight off" as a finding, because no trial on this site or anywhere else is offered to support it
- You are buying tirzepatide and relying on the footnote, which describes a semaglutide dose
- You want to know which trial, which population and which follow-up period any of these numbers came from
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Named
None found
Provenance
Products reviewed at Edessa
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Advertised from $135, which is the six-month plan; a single month is $179.
- Compounded tirzepatide injection — $239 a month, or $209 on the six-month plan.
- Compounded oral semaglutide tablet — $229 a month, or $199 on the six-month plan — the dearest of the three products.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
3
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not Edessa's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Edessa’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)No trial supports this claim
“It works. On average, patients lose 15-20% of their body weight. 18% Average weight loss. Nine out of ten patients call it the most effective treatment to date. 6.5" Potential waist reduction. 93% Kept the weight off.”
Read on the Edessa site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults with a body-mass index of 30 or above, or 27 or above with a weight-related condition. Reported a mean weight reduction of about 15% on semaglutide 2.4 mg against about 2% on placebo. The trial's own extension followed participants after they stopped and reported that most of the lost weight came back.
The 15-20% range is in the right neighborhood for this molecule, and that is the only one of the five figures that is. The other four have no trial behind them and one of them contradicts the trial record. "93% Kept the weight off" is presented without a follow-up period, without a definition of what keeping it off means, and without a source — while the STEP 1 extension, which followed the same drug in the same population, reported that participants regained most of what they had lost after stopping. A 6.5-inch waist reduction and nine patients in ten calling this the most effective treatment they have tried are survey-shaped claims with no survey attached. All five sit under a heading reading "clinical data", and the subject of the sentence is Edessa's own patients rather than anybody in a trial.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)No trial supports this claim
“*Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.”
Read on the Edessa site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults with obesity or overweight and no diabetes. Tirzepatide was dosed at 5, 10 and 15 mg once weekly. No arm of this trial used 2.4 mg.
The footnote that qualifies the weight-loss claim on this page describes a dose of the wrong drug. 2.4 mg a week is the semaglutide maintenance dose used in STEP 1; tirzepatide is dosed at 5, 10 or 15 mg, and no arm of SURMOUNT-1 used 2.4 mg of anything. The same footnote appears word for word on all four of Edessa's product pages, which is how it got here — it was written once for semaglutide and pasted everywhere. The effect is that the only sentence on the tirzepatide page qualifying what weight loss to expect describes a treatment this page does not sell.2
Compounded oral semaglutide tabletSemaglutide · Compounded (503A)Claim reaches past the trials
“Daily GLP-1 weight loss tablets. GLP-1 tablets are taken once daily.”
Read on the Edessa site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested semaglutide as a once-weekly injection at 2.4 mg. It is not a trial of a daily compounded tablet, and no dose equivalence between the two forms is established by it.
Edessa sells the tablet beside the injection, under the same efficacy figures and the same footnote, and the footnote describes a weekly injection at 2.4 mg. A daily compounded tablet is a different product: the dose, the absorption and the amount of drug needed are all different, and no trial cited anywhere on this site tested one. Nothing on the page says which of the five headline numbers is supposed to apply to it.1
Dispensing chain
Who actually fills your prescription
- Health Warehouse
- Precision Compounding Pharmacy
Read the full account
Edessa names two pharmacies in its terms, one of them with a full street address and telephone number: Health Warehouse in Florence, Kentucky, and Precision Compounding Pharmacy. That is real disclosure, and most of this market does not offer it. The same pharmacies are named by other sellers we review, which tells you they are shared suppliers and nothing at all about who owns whom. What is missing is the tier: nothing says whether either pharmacy makes the drug to order under a prescription or dispenses it off a shelf, and the prescribing side is not named at any level — no clinician, no medical director, no advisory panel.
Read on the Edessa site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere on the site. What Edessa publishes instead is scale it does not source — "Join 100,000+ successful GLP-1 patients" rides the top of every page, with no date and no definition of what made those patients successful. A weight-loss money-back guarantee is badged on the homepage, and its conditions appear on no page of the site — not the homepage, not the product pages, not the terms. Against that, the compounding disclaimer is better placed than most: "Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA" sits directly above every price table rather than in a footer.
Read on the Edessa site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Edessa publishes no list of states and claims no nationwide coverage. Its terms give a Las Vegas business address and no service area, checked across the homepage, the three product pages and the terms in September 2026.
Read the full licensing claim
Its terms describe the operator as "Edessa Group, LLC, a Nevada corporation" — two different corporate forms for the same company in a single clause. No clinician is named anywhere on the site; every product page offers only "board-certified provider consultation".
Read on the Edessa site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names two dispensing pharmacies, one with a full street address and telephone number.
- Its compounding disclaimer sits directly above every price table rather than buried in a footer.
- That disclaimer is accurate — it says compounded products are not approved or evaluated by the FDA.
Show 3 more
- It publishes its own business address, which several sellers we review do not.
- The 15-20% range it quotes for average weight loss is in the right neighborhood for this molecule.
- No FDA warning letter, for Edessa or for either pharmacy it names.
- Five statistics sit under a heading reading "clinical data" and not one names a trial, a journal or a date.
- "93% Kept the weight off" is published with no follow-up period and no definition of keeping it off.
- The trial record points the other way — STEP 1's own extension found most of the lost weight returned after stopping.
Show 8 more
- The tirzepatide page's efficacy footnote describes 2.4 mg a week, which is a semaglutide dose.
- That same footnote appears word for word on all four product pages, including the daily tablet.
- The tablet is sold under the same numbers as the injection, with no trial of a tablet cited anywhere.
- "Nine in ten patients call it the most effective treatment" is a survey claim with no survey attached.
- "Join 100,000+ successful GLP-1 patients" carries no date and no definition of successful.
- A money-back guarantee is badged on the homepage with its conditions published nowhere we could find.
- Its terms call the same company both an LLC and a corporation in one sentence.
- No clinician is named anywhere — no prescriber, no medical director, no advisory panel.
Verdict
The bottom line
Two things here beat the market average: the pharmacies are named, and the compounding warning is in the right place. The numbers are the problem. Before you treat any of the five as a finding, ask Edessa for the source — which trial, which population, how long the follow-up ran. If you are buying tirzepatide, ask separately why the footnote explaining your expected weight loss describes a dose of semaglutide.
Opens Edessa's website. A link is not a recommendation to take anything.
Read the guarantee alongside the order terms
The public homepage reviewed October 13 advertises a results-based money-back guarantee, expedited delivery and prices including medication, consultation and shipping. These are seller promises, not refunds or deliveries we have tested. The guarantee language alone does not settle the assessment period, evidence required, deadline or refund amount for an individual order. 3
Before choosing a longer plan, request those conditions and the total commitment in writing. Also distinguish the branded trial evidence from Edessa’s described self-reported customer data: an outcome observed among responding customers does not establish the result a new patient should expect.
Full analysis — 4 more sectionsThe heading says "clinical data" · The one that runs backwards · The footnote on the wrong drug · What Edessa gets right
The heading says "clinical data"
On Edessa's homepage, under "Why are so many patients signing up for Edessa?":
"It works. On average, patients lose 15-20% of their body weight."
Then four figures in a row:
18% Average weight loss
Nine in ten patients call it the most effective treatment to date
6.5" Potential waist reduction
93% Kept the weight off
The block is headed CLINICAL DATA. None of the five numbers names a trial, a journal, a year, a sample size or a follow-up period.
Note the subject of that first sentence. It isn't trial participants — it's "patients", Edessa's own. So a reader can't tell whether they're being shown published results, internal figures, or neither.
The one that runs backwards
Of the five, "93% Kept the weight off" is the one worth stopping at.
Whether weight stays off is the best-documented weakness of this drug class, not a strength. STEP 1 randomized 1,961 adults for 68 weeks and reported a mean reduction of about 15%. 1 Its own extension then followed participants after they stopped taking the drug — and reported that most of the lost weight came back.
Edessa gives no follow-up period and no definition of what "kept off" means. Kept off for how long, measured from when, in how many people? A number that high, on that question, would be the most interesting finding in the field.
The footnote on the wrong drug
Every Edessa page carries the same efficacy footnote:
"*Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity."
2.4 mg a week is the semaglutide maintenance dose — the dose STEP 1 used. 1
Tirzepatide is dosed at 5, 10 or 15 mg. SURMOUNT-1 tested those three and nothing else. 2
So on the page selling compounded tirzepatide, the single sentence telling you where the weight-loss figure came from describes a dose of a different molecule. Across all four product pages the footnote never changes — it was written once and pasted everywhere, including onto the daily tablet.
What Edessa gets right
Directly above every price table, in ordinary type:
"Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA."
That is accurate, it is unhedged, and it is in the place a buyer will actually read it. Its terms also name two pharmacies — Health Warehouse in Florence, Kentucky, with a street address and phone number, and Precision Compounding Pharmacy. Plenty of sellers name none.
The gap is between those two disclosures and the five numbers on the front page. One half of this site is careful. The other half publishes a maintenance rate the literature doesn't support, under a heading that calls it clinical data.
Questions
Frequently asked questions
Where do Edessa's weight-loss numbers come from?
The site doesn't say. The 18% average, the 93% maintenance rate, the 6.5-inch waist reduction and the nine-in-ten satisfaction figure all appear under a "clinical data" heading with no trial, journal, year or sample size attached. The 15-20% range it quotes elsewhere is roughly right for this molecule, which makes the silence around the other four more noticeable rather than less.
Is "93% kept the weight off" plausible?
Not on the published record, and this is the question the drug class is weakest on. STEP 1's extension followed the same molecule in the same kind of population after people stopped taking it, and found most of the lost weight returned. Edessa gives no follow-up period and no definition of keeping it off, so there is nothing to check the figure against.
Why does the tirzepatide page mention 2.4 mg?
Because the footnote was written for semaglutide and pasted onto every page. 2.4 mg a week is the semaglutide maintenance dose from STEP 1. Tirzepatide is dosed at 5, 10 or 15 mg, and SURMOUNT-1 tested only those — so the sentence explaining your expected weight loss on that page describes a treatment the page doesn't sell.
Does the tablet work like the injection?
Nothing on this site establishes that, and Edessa sells both under the same figures. Oral semaglutide is absorbed very differently from an injection and generally needs far more drug to reach a comparable exposure. No trial of a compounded daily tablet is cited anywhere on the site.
Which pharmacy fills an Edessa prescription?
Its terms name Health Warehouse in Florence, Kentucky, with an address and a phone number, and Precision Compounding Pharmacy. Naming any pharmacy at all puts Edessa ahead of most sellers. What it doesn't say is whether either makes the medication to order or dispenses it ready-made.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021. It is the study almost every semaglutide weight-loss claim ultimately rests on.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks, at 5, 10 and 15 mg. Published in the New England Journal of Medicine in 2022.
- Compounded
- Made to order by a pharmacy for an individual patient, rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved, and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Edessa sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Edessa is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Edessa's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, entry at BMI ≥30 or ≥27 with at least one weight-related condition. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the Edessa site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.